AIMM Therapeutics B.V. – Product Pipeline Review

Global Markets Direct’s, ‘AIMM Therapeutics B.V. – Product Pipeline Review – 2016’, provides an overview of the AIMM Therapeutics B.V.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AIMM Therapeutics B.V., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of AIMM Therapeutics B.V.

The report provides overview of AIMM Therapeutics B.V. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses AIMM Therapeutics B.V.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features AIMM Therapeutics B.V.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate AIMM Therapeutics B.V.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for AIMM Therapeutics B.V.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding AIMM Therapeutics B.V.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

AIMM Therapeutics B.V. Snapshot 6

AIMM Therapeutics B.V. Overview 6

Key Information 6

Key Facts 6

AIMM Therapeutics B.V. - Research and Development Overview 7

Key Therapeutic Areas 7

AIMM Therapeutics B.V. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

AIMM Therapeutics B.V. - Pipeline Products Glance 14

AIMM Therapeutics B.V. - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

AIMM Therapeutics B.V. - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

AIMM Therapeutics B.V. - Unknown Stage Pipeline Products 17

Unknown Products/Combination Treatment Modalities 17

AIMM Therapeutics B.V. - Drug Profiles 18

CR-8020 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Monoclonal Antibody for Acute Myelocytic Leukemia 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Monoclonal Antibody for Colon Carcinoma 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Monoclonal Antibody for Cytomegalovirus Infections 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Monoclonal Antibody for Hepatitis C Infection 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Monoclonal Antibody for Human Rhinovirus Infections 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody for Melanoma 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibody for MRSA Infections 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibody for Multiple Myeloma 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibody for Oncology 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibody for Pancreatic Cancer 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

AM-18 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

AM-28 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody for Clostridium Difficile Infections 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibodies for Hepatitis B Infection 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

AIMM Therapeutics B.V. - Pipeline Analysis 35

AIMM Therapeutics B.V. - Pipeline Products by Target 35

AIMM Therapeutics B.V. - Pipeline Products by Route of Administration 36

AIMM Therapeutics B.V. - Pipeline Products by Molecule Type 37

AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action 38

AIMM Therapeutics B.V. - Locations And Subsidiaries 39

Head Office 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Tables

List of Tables

AIMM Therapeutics B.V., Key Information 6

AIMM Therapeutics B.V., Key Facts 6

AIMM Therapeutics B.V. – Pipeline by Indication, 2016 8

AIMM Therapeutics B.V. – Pipeline by Stage of Development, 2016 10

AIMM Therapeutics B.V. – Monotherapy Products in Pipeline, 2016 11

AIMM Therapeutics B.V. – Out-Licensed Products in Pipeline, 2016 12

AIMM Therapeutics B.V. – Out-Licensed Products/ Combination Treatment Modalities, 2016 13

AIMM Therapeutics B.V. – Phase II, 2016 14

AIMM Therapeutics B.V. – Preclinical, 2016 15

AIMM Therapeutics B.V. – Discovery, 2016 16

AIMM Therapeutics B.V. – Unknown, 2016 17

AIMM Therapeutics B.V. – Pipeline by Target, 2016 35

AIMM Therapeutics B.V. – Pipeline by Route of Administration, 2016 36

AIMM Therapeutics B.V. – Pipeline by Molecule Type, 2016 37

AIMM Therapeutics B.V. – Pipeline Products by Mechanism of Action, 2016 38

List of Figures

List of Figures

AIMM Therapeutics B.V. – Pipeline by Top 10 Indication, 2016 8

AIMM Therapeutics B.V. – Pipeline by Stage of Development, 2016 10

AIMM Therapeutics B.V. – Monotherapy Products in Pipeline, 2016 11

AIMM Therapeutics B.V. – Pipeline by Target, 2016 35

AIMM Therapeutics B.V. – Pipeline by Route of Administration, 2016 36

AIMM Therapeutics B.V. – Pipeline by Molecule Type, 2016 37

AIMM Therapeutics B.V. – Pipeline Products by Mechanism of Action, 2016 38

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared